Cann Group Ltd. ( (AU:CAN) ) has issued an announcement.
Cann Group Limited has announced changes to its board of directors, with Mr. Peter Kopanidis joining as a Non-executive Director and Mr. Robert Barnes retiring from the same position. Peter Kopanidis brings over 30 years of experience in finance across various industries, which is expected to be beneficial for Cann Group as it navigates its current stage of development. The board chair, Doug Rathbone, expressed gratitude for Robert Barnes’ contributions, particularly his insights into the pharmaceutical sector, and welcomed Peter’s expertise in corporate finance and investor relations.
More about Cann Group Ltd.
Cann Group Limited is a company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. With research facilities and corporate headquarters in Melbourne, the company operates a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group provides a variety of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to both Australian and international markets. Additionally, the company owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: 54.55%
Average Trading Volume: 1,400
Technical Sentiment Signal: Buy
Current Market Cap: $8.72M
See more data about CAN stock on TipRanks’ Stock Analysis page.